IgG3 deficiency (<0.3 g/L) correlates with Wiskott-Aldrich syndrome, systemic lupus erythematosus (SLE), and recurrent bacterial/viral infections due to impaired immune complex clearance. In SLE models, IgG3 deposits drive glomerulonephritis via FcγR-mediated neutrophil activation, while its deficiency attenuates renal damage. Paradoxically, early IgG3 responses in acute infections (e.g., CHIKV) correlate with severe initial symptoms but prevent chronic arthralgia by rapid viral clearance. Clinically, IgG3’s short half-life (7 days vs. IgG1’s 21 days) stems from Arg435-mediated FcRn competition, though the H435 allotype extends half-life for therapeutic use. Anti-HIV IgG3 antibodies peak within 4–5 months post-infection, serving as transient biomarkers for recent exposure6. Hinge-length polymorphisms (3 vs. 4 repeats) influence COVID-19 severity, with shorter hinges impairing viral neutralization and increasing mortality risk. Engineered IgG3 variants with stabilized hinges enhance phagocytosis 3-fold, offering promise for antibody therapeutics targeting intracellular pathogens.

Common uses include ELISA standards, IVD Assay standards, calibrators and controls, therapeutics research, immune system research.